Skip to main content
Fig. 7 | Biology Direct

Fig. 7

From: Phosphodiesterase type 5 inhibitor tadalafil reduces prostatic fibrosis via MiR-3126-3p/FGF9 axis in benign prostatic hyperplasia

Fig. 7

Mechanistic depiction of PDE5 inhibitor-mediated inhibition of prostatic FMT process. Tadalafil can counteract the inhibitory impact of TGFβ1 on miR-3126-3p, ultimately boosting the expression of miR-3126-3p. Following this, miR-3126-3p selectively binds to the 3’UTR region of FGF9 mRNA, thereby curtailing both the translation and secretion of FGF9. This intricate series of events culminates in the suppression of FMT differentiation within the prostate

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us